REVEALED: Intellia | Rare Historical Photos

Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity

Here's how to play leading gene-editing stocks as Anthropic's AI tools make progress in the gene-editing space.

Barchart · Sep 29

A One Time CRISPR Infusion for Hereditary Angioedema Now Has a March Decision Date and No Advisory Panel

FDA accepted a priority review for lonvo-z, a one-time CRISPR treatment for hereditary angioedema, with a decision target of March 10, 2027.

Medical Daily · Sep 9

Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying

Despite Intellia's severe stock drop from its 2021 peak, Cathie Wood is buying big.

Barchart · May 5

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

Intellia Therapeutics Inc. (NASDAQ:NTLA) shares tumbled after the company said it had temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of its experimental CRISPR therapy, nexiguran ziclumeran (nex-z), following a serious liver-related adverse event in one participant.

Benzinga · Oct 27, 2025

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).

Benzinga · Sep 25, 2025

Intellia Therapeutics Shares Are Ripping Higher: Here's Why

Intellia Therapeutics Inc (NASDAQ:NTLA) shares are soaring on Thursday after the company completed enrollment in its crucial Phase 3 HAELO trial and laid out its key development milestones.

Benzinga · Sep 18, 2025

Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here?

Cathie Wood recently acquired shares of the biotech company. Should you do the same?

Barchart · Aug 21, 2025

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.

MarketBeat · Jul 15, 2025

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

This clinical-stage biotech stock has a strong pipeline capable of creating the next Moderna.

Barchart · Jul 8, 2025

Analysts Think These Stocks Could More Than Double in Value

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

MarketBeat · May 23, 2025